Urticaria relapse after mRNA COVID-19 vaccines in patients affected by chronic spontaneous urticaria and treated with antihistamines plus omalizumab: A single-center experience.
Dermatol Ther
; 35(11): e15838, 2022 11.
Article
in English
| MEDLINE | ID: covidwho-2029319
ABSTRACT
Urticaria is a disease characterized by wheals and/or angioedema. Chronic spontaneous urticaria (CSU) occurs for longer than 6 weeks and appears independently of any identifiable exogenous stimulus. During the vaccination campaign for Coronavirus disease 2019 (COVID-19) pandemic, several cutaneous adverse events have been described, among which urticaria lasting less than 6 weeks (acute urticaria, AU). AU due to vaccines can be IgE or non-IgE mediated; the former typically develop within 4 h of drug exposure, the latter occurs later and the mechanism is unclear. In this retrospective study we analyzed the frequency and clinical characteristics of urticaria occurring after COVID-19 vaccine (post-vaccination urticaria relapse) in adult CSU patients treated with antihistamine and omalizumab, and in clinical remission.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Urticaria
/
Anti-Allergic Agents
/
Chronic Urticaria
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Adult
/
Humans
Language:
English
Journal:
Dermatol Ther
Journal subject:
Dermatology
Year:
2022
Document Type:
Article
Affiliation country:
Dth.15838
Similar
MEDLINE
...
LILACS
LIS